Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

This PQI in Action is a follow up to the Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations PQI and explores how the medically integrated teams at Florida Cancer Specialists & Research Institute, Mayo Clinic, and Texas Oncology collaborate and utilize the information found in the PQI as part of their daily practice.